CoChat
Sign Up
Cited by 584

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

Mahon, François Xavier, Deininger, Michael W. N., Schultheis, Beate, Chabrol, Jérome, Reiffers, Josy, Goldman, John M., Melo, Junia V.·2000·Blood
DOI 10.1182/blood.v96.3.1070
Open this paper in CoChat — free account

Abstract

Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is an attractive therapeutic strategy in chronic myelogenous leukemia (CML). A few CML cell lines and primary progenitors are, however, resistant to this compound. We investigated the mechanism of this resistance in clones of the murine BaF/3 cells transfected with BCR-ABL and in 4 human cell lines from which sensitive (s) and resistant (r) clones were generated by various methods. Although the resistant cells were able to survive in the presence of STI571, their proliferation was approximately 30% lower than that of their sensitive counterparts in the absence of the compound. The concentration of STI571 needed for a 50% reduction in viable cells after a 3-day exposure was on average 10 times higher in the resistant (2-3 μmol/L) than in the sensitive (0.2-0.25 μmol/L) clones. The mechanism of resistance to STI571 varied among the cell lines. Thus, in Baf/BCR-ABL-r, LAMA84-r, and AR230-r, there was up-regulation of the Bcr-Abl protein associated with amplification of the BCR-ABL gene. In K562-r, there was no Bcr-Abl overexpression, but the IC50 for the inhibition of Bcr-Abl autophosphorylation was increased in the resistant clones. Sequencing of the Abl kinase domain revealed no mutations. The multidrug resistance P-glycoprotein (Pgp) was overexpressed in LAMA84-r, indicating that at least 2 mechanisms of resistance operate in this cell line. KCL22-r showed neither Bcr-Abl up-regulation nor a higher threshold for tyrosine kinase inhibition by STI571. We conclude that BCR-ABL–positive cells can evade the inhibitory effect of STI571 by different mechanisms, such as Bcr-Abl overexpression, reduced intake mediated by Pgp, and, possibly, acquisition of compensatory mutations in genes other than BCR-ABL.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v96.3.1070

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 36

  1. Melo, 1996, The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype., Blood., 88, 2375, 10.1182/blood.V88.7.2375.bloodjournal8872375 · DOI
  2. Daley, 1990, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome., Science., 247, 824, 10.1126/science.2406902 · DOI
  3. Lugo, 1990, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products., Science., 247, 1079, 10.1126/science.2408149 · DOI
  4. Okabe, 1992, Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth., Blood., 80, 1330, 10.1182/blood.V80.5.1330.1330 · DOI
  5. Anafi, 1993, Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate., Blood., 82, 3524, 10.1182/blood.V82.12.3524.3524 · DOI
  6. Buchdunger, 1996, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative., Cancer Res., 56, 100
  7. Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells., Nat Med., 2, 561, 10.1038/nm0596-561 · DOI
  8. Deininger, 1997, The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells., Blood., 90, 3691, 10.1182/blood.V90.9.3691 · DOI
  9. Gambacorti-Passerini, 1997, Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis., Blood Cells Mol Dis., 23, 380, 10.1006/bcmd.1997.0155 · DOI
  10. Druker, 1999, Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP57148 in interferon refractory chronic myelogenous leukemia patients [abstract]., J Clin Oncol., 18, 7a
  11. Daley, 1988, Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein., Proc Natl Acad Sci U S A., 85, 9312, 10.1073/pnas.85.23.9312 · DOI
  12. Mahon, 1995, Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction., Exp Hematol., 23, 1606
  13. Dan, 1998, Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase CGP 57148., Cell Death Differ., 5, 710, 10.1038/sj.cdd.4400400 · DOI
  14. Kabarowski, 1994, A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells., EMBO J., 13, 5887, 10.1002/j.1460-2075.1994.tb06934.x · DOI
  15. Chomczynski, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction., Anal Biochem., 162, 156, 10.1016/0003-2697(87)90021-2 · DOI
  16. Shah, 1991, Characterization of BCR promoter in Philadelphia chromosome-positive and negative cell lines., Mol Cell Biol., 11, 1854, 10.1128/MCB.11.4.1854 · DOI
  17. Zhu, 1990, Unique organization of the human BCR gene promoter., Nucleic Acids Res., 18, 7119, 10.1093/nar/18.23.7119 · DOI
  18. Wu, 1995, Extensive amplification of bcr/abl fusion genes clustered on the three marker chromosome in human leukemic cell line K-562., Leukemia., 9, 858
  19. Vossebeld, 1999, Reversal of multidrug resistance in hematological malignancies., Blood Rev., 13, 67, 10.1016/S0268-960X(99)90013-9 · DOI
  20. Shtivelman, 1985, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia., Nature., 315, 550, 10.1038/315550a0 · DOI
  21. Fainstein, 1989, Nucleotide sequence analysis of human abl and bcr-abl cDNAs., Oncogene., 4, 1477
  22. Carroll, 1997, CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins., Blood., 90, 4947, 10.1182/blood.V90.12.4947 · DOI
  23. le Coutre, 1999, In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor., J Natl Cancer Inst., 91, 163, 10.1093/jnci/91.2.163 · DOI
  24. Arceci, 1993, Clinical significance of P-glycoprotein in multidrug resistance malignancies., Blood., 81, 2215, 10.1182/blood.V81.9.2215.2215 · DOI
  25. Belloc, 1997, Bcr-Abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines., Cell Death Differ., 4, 806, 10.1038/sj.cdd.4400303 · DOI
  26. Campos, 1992, Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis., Blood., 79, 473, 10.1182/blood.V79.2.473.473 · DOI
  27. Lemontt, 1988, Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells., Cancer Res., 48, 6343
  28. Wu, 1999, Bcr: a negative regulator of the Bcr-Abl oncoprotein., Oncogene., 31, 4416, 10.1038/sj.onc.1202828 · DOI
  29. Wickremasinghe, 1999, Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies., Blood., 93, 3587, 10.1182/blood.V93.11.3587 · DOI
  30. Rustum, 1979, Correlation between leukemic cell retention of 1-B-arabinofurasylcytosine 5'-triphosphate and response to therapy., Cancer Res., 39, 42
  31. Sonneveld, 1981, Differences in uptake of adriamycin and daunorubicin by normal BM cells and acute leukemia cells determined by flow cytometry., Leuk Res., 5, 251, 10.1016/0145-2126(81)90110-7 · DOI
  32. Hart, 1994, Expression of multidrug resistance-associated protein (MRP) in acute leukaemia., Leukemia., 8, 2163
  33. Rowley, 1982, Chromosome abnormalities in malignant hematologic diseases., Adv Cancer Res., 36, 1477
  34. Gaiger, 1995, Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression., Blood., 86, 2371, 10.1182/blood.V86.6.2371.bloodjournal8662371 · DOI
  35. Lin, 1995, Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia., Genes Chromosomes Cancer., 13, 110, 10.1002/gcc.2870130207 · DOI
  36. Kuwazuru, 1990, Expression of multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis., Br J Haematol., 74, 24, 10.1111/j.1365-2141.1990.tb02533.x · DOI

Cited by

Sorted by citations

See all 584

Metadata

Authors
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V.
Venue
Blood
Publisher
American Society of Hematology
Published
2000-08-01
Volume
96
Issue
3
Pages
1070-1079
ISSN
  • 1528-0020
  • 0006-4971
DOI
10.1182/blood.v96.3.1070
Cited by
584
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review